SCHEMBL25548714

SCHEMBL25548714

CC(C)(C)[C@H](NC(=O)c1ccc2cc(F)ccc2c1OCc1ccc(S(F)(F)(F)(F)F)cc1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 2/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.35
▸ FCER2 P06734 1/20 0.34
▸ GRM5 P41594 1/20 0.33
▸ ITGB3 P05106 1/20 0.33
▸ ITGB1 P05556 1/20 0.33
▸ ITGAV P06756 1/20 0.33
▸ ITGA5 P08648 1/20 0.33
▸ PDE2A O00408 3/20 0.33
▸ MAOB P27338 3/20 0.32
▸ MAOA P21397 2/20 0.32
▸ CNR1 P21554 2/20 0.32
▸ CNR2 P34972 2/20 0.32
▸ ABHD12 Q8N2K0 1/20 0.32
▸ PYGL P06737 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ MME P08473 1/20 0.32
▸ ACE P12821 1/20 0.32
▸ CPA1 P15085 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25549762 1.00 CXCR2 (0.38) CXCR2FFAR4FCER2GRM5ITGB3
SCHEMBL25548976 0.91 CXCR2 (0.36) CXCR2FFAR4ITGB3ITGB1ITGAV
SCHEMBL38662651 0.88 CXCR2 (0.50) CXCR2FFAR4GRM5MAOBLRRK2
SCHEMBL23460975 0.88 CXCR2 (0.50) CXCR2FFAR4GRM5MAOBLRRK2
SCHEMBL23460977 0.88 CXCR2 (0.50) CXCR2FFAR4GRM5MAOBLRRK2
SCHEMBL25549824 0.88 CXCR2 (0.49) CXCR2PDE2AMAOACNR1CNR2
SCHEMBL25548728 0.88 CXCR2 (0.49) CXCR2PDE2AMAOACNR1CNR2
SCHEMBL25548880 0.88 CXCR2 (0.37) CXCR2FFAR4ITGB3ITGB1ITGAV
SCHEMBL25549545 0.88 CXCR2 (0.38) CXCR2FFAR4FCER2GRM5MAOB
SCHEMBL25560540 0.88 CXCR2 (0.38) CXCR2FFAR4FCER2GRM5MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885FFAR4 2302/4885FCER2 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback